Barclays PLC Moon Lake Immunotherapeutics Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Barclays PLC holds 4,553 shares of MLTX stock, worth $41,705. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,553

Previous 4,553 -0.0%

Holding current value

$41,705

Previous $215,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$32.84 - $51.05 $494,110 - $768,098	-15,046 Reduced 76.77%	4,553 $215,000
Q1 2025 May 15, 2025	BUY	$36.75 - $54.34 $549,522 - $812,546	14,953 Added 321.85%	19,599 $766,000
Q4 2024 Feb 13, 2025	SELL	$45.84 - $57.91 $45,610 - $57,620	-995 Reduced 17.64%	4,646 $252,000
Q3 2024 Nov 15, 2024	BUY	$40.15 - $55.4 $209,944 - $289,686	5,229 Added 1269.17%	5,641 $283,000
Q2 2024 Aug 14, 2024	SELL	$38.43 - $48.6 $129,393 - $163,636	-3,367 Reduced 89.1%	412 $18,000
Q1 2024 May 15, 2024	SELL	$43.78 - $63.86 $102,226 - $149,113	-2,335 Reduced 38.19%	3,779 $190,000
Q4 2023 Feb 15, 2024	BUY	$36.35 - $63.02 $101,852 - $176,582	2,802 Added 84.6%	6,114 $369,000
Q3 2023 Nov 07, 2023	BUY	$48.35 - $61.26 $160,135 - $202,893	3,312 New	3,312 $189,000
Q4 2022 Feb 13, 2023	BUY	$7.05 - $10.5 $287,414 - $428,064	40,768 Added 268.49%	55,952 $587,000
Q3 2022 Nov 03, 2022	BUY	$5.25 - $9.27 $530 - $936	101 Added 0.67%	15,184 $118,000
Q2 2022 Aug 12, 2022	BUY	$4.69 - $13.25 $70,739 - $199,849	15,083 New	15,083 $79,000

Others Institutions Holding MLTX

# of Institutions

157

Shares Held

54.5M

Call Options Held

799K

Put Options Held

661K

View Full List

About MoonLake Immunotherapeutics

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $338M
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

More about MLTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account